Edgestream Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.26M	Sell	191,328 -124,911	-39%	-$2.99M	0.14%	282
2025 Q4	$8.45M	Buy	316,239 +82,394	+35%	+$1.97M	0.24%	99
2025 Q3	$4.99M	Buy	233,845 +122,701	+110%	+$2.9M	0.15%	252
2025 Q2	$2.4M	Sell	111,144 -47,964	-30%	-$892K	0.07%	488
2025 Q1	$2.64M	Sell	159,108 -105,282	-40%	-$1.91M	0.09%	417
2024 Q4	$4.85M	Buy	264,390 +45,061	+21%	+$727K	0.21%	165
2024 Q3	$3.37M	Buy	219,329 +128,372	+141%	+$2.14M	0.15%	232
2024 Q2	$1.48M	Buy	90,957 +29,051	+47%	+$469K	0.07%	423
2024 Q1	$1.14M	Buy	61,906 +23,998	+63%	+$595K	0.06%	467
2023 Q4	$1.19M	Buy	37,908 +28,205	+291%	+$674K	0.09%	390
2023 Q3	$202K	Sell	9,703 -74,467	-88%	-$2.02M	0.02%	786
2023 Q2	$2.02M	Buy	+84,170	New	+$1.87M	0.18%	189